A 103
Alternative Names: A-103Latest Information Update: 04 May 2022
At a glance
- Originator Osteal Therapeutics
- Class Antifungals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bone and joint infections
Most Recent Events
- 20 Apr 2022 Preclinical trials in Bone and joint infections in USA (unspecified route) (Osteal Therapeutics pipeline; April 2022)